Todd Dunn of Accuryn Medical

Kidneys are a vital organ, but most hospitals still manage them with a gravity-fed catheter invented in 1933 and a blood test that was never designed to be a kidney marker. Todd Dunn, CEO of Accuryn, joins the show to talk about why acute kidney injury is one of the most overlooked patient safety problems in healthcare and how his team is digitizing kidney function at the bedside.Todd spent years leading innovation at GE Healthcare, Intermountain Healthcare, and Atrium Health before becoming an Accuryn customer and eventually stepping into the CEO role. In this conversation, we get into his innovation background, the staggering scale of AKI across U.S. hospitals (over 3 million events per year), the CMS decision to declare AKI a hospital-acquired harm, and how Accuryn's technology provides real-time urine output and intra-abdominal pressure data that can flag kidney distress up to 12 hours ahead of standard blood testing.We also talk about CAUTI reduction (90%+ in some units), where early adoption is happening, the nursing efficiency gains, and where Todd sees this heading with agentic AI and a more complete hemodynamic picture of the patient.Topics covered:Todd's innovation career from GE to Intermountain to Atrium to AccurynWhy kidneys are still managed with 90-year-old technologyAKI prevalence, readmission rates, mortality impact, and cost dataHow Accuryn's active drain line clearance and ultrasonic measurement workReal-time EMR integration with Epic and CernerIntra-abdominal pressure monitoring at 100 readings per secondCAUTI reduction data from burn units and ICUsCMS hospital-acquired harm designation and what it means for health systemsThe future role of agentic AI in hemodynamic monitoringTodd's upcoming book on systematic healthcare innovationConnect with Todd directly: [email protected]